Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications -
- Initiation of both Phase 3 trials is expected by end of January 2022 -
https://finance.yahoo.com/news/reviva-pharmaceuticals-holdings-inc-receives-110000744.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.